Discovery & Development

Drugs often fail , both before and after reaching the market - but why?

One of the biggest pharma trade shows in Europe kicks off at the end of October

Each new drug is unique and deserves a fresh approach to formulation.

Why stop at biosimilar when you can be biobetter?

When looking to do good, many companies choose to focus on children’s health, particularly in developing countries.

The potential of inhaled drug delivery goes beyond traditional respiratory medicine.

If pharma wants to adopt continuous manufacturing, it must employ control procedures to ensure quality.

With approximately 80 percent of new drugs suffering from poor solubility and bioavailability, understanding solid form is more important than ever.

High-throughput excipient discovery looks set to boost oral bioavailability.

Nasal-bound nanoparticles could offer a novel way to bypass the blood-brain barrier